Numbers

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The Numbers

Sammaan Capital trades at 0.53x book value because the market cannot yet see a path back to double-digit returns on equity. This was India's second-largest housing finance company at its peak — $2,461M revenue, 33% operating margins, 27% ROE in FY2019 — before the NBFC liquidity crisis hollowed it out. Six years later, revenue has halved, ROE sits under 6%, and the loan book has been deliberately shrunk. The single metric that will re-rate or de-rate this stock is ROE: at 5.9% normalized returns on $255M of equity, a sub-book valuation is mathematically fair. If the new controlling shareholder (Abu Dhabi's IHC, acquiring 41.5% for $104M) can push ROE above 12% through the diversified lending pivot, the stock reprices toward book value — an 88% move from here.

At a Glance

Book value per share is $2.88 (post-IHC equity infusion). Normalized TTM P/E is 9.3x, using the four clean quarters (Q4 FY2025 through Q3 FY2026). Reported TTM P/E including the one-time charge is negative and meaningless. Zero promoter holding — the former Indiabulls group exited entirely; IHC's 41.5% acquisition makes them the new anchor.

Revenue & Earnings — Rise, Crash, Stabilize

Revenue peaked at $2,461M in FY2019 then collapsed over five years as the company deliberately shrank its loan book post-crisis. The book has stabilized around $1,000-1,060M since FY2023. The FY2025 net loss is entirely the one-time provision; normalized net income runs at ~$150M annually.

Net Interest Income — The Spread Is Healing

This is the chart the headline revenue number hides. NII — the spread between what the company earns on loans and pays on borrowings — recovered 25% from its FY2022 trough of $363M to $455M in FY2025, even as total revenue flatlined. Borrowing costs are falling faster than lending income because the deleveraging is improving unit economics. In the peak years, 56% of NII reached net income; today only 37% does, because the cost base has not shrunk as fast as the revenue. That is the operating efficiency problem IHC needs to fix.

Quarterly Pulse — Stable Profits, Clean Book

Strip out the Q2 FY2025 cliff and quarterly profits have been steady at $32-39M for 13 consecutive normal quarters, with a slight upward drift. The business is operationally stable — it is just not growing yet.

The massive Q2 FY2025 write-off achieved its purpose: GNPA dropped from 2.68% to 1.30% in a single quarter as legacy stressed assets were written off. Net NPA is now at 0.80%, the cleanest the book has been in years. This was a deliberate pre-acquisition cleanup — take the pain upfront, hand IHC a clean book.

Return on Equity — Why It Trades Below Book

This chart explains the entire stock price. ROE went from a best-in-class 27-31% (FY2014-2019) to a structurally impaired 7% (FY2022-2024). At 7% ROE, the stock should trade at 0.5-0.6x book — which is exactly where it is. The FY2025 dip to -9% is the one-time charge. Normalized ROE is ~5.9% (pre-IHC equity base) or ~4.1% (post-IHC dilution, before capital deployment). The IHC equity injection temporarily suppresses ROE further until the capital is deployed into earning assets.

Balance Sheet — The Great Deleveraging

Borrowings declined from $1,703M at peak (FY2018) to $500M (FY2025) — a 71% reduction in dollar terms. Debt-to-equity compressed from 7.7x to 2.0x over seven years, well below the 5-7x typical for HFCs. This was survival, not optimization: during the NBFC crisis, wholesale funding markets froze and the company had to repay maturing debt by running down its loan book. The balance sheet is now conservatively capitalized. Total assets shrank from $2,034M to $821M. Dividends were suspended in FY2022 and remain near zero (current yield: 0%).

Valuation — Price-to-Book vs 10-Year History

The stock went from 3.6x book (when the market priced 25%+ ROE sustainability) to 0.3x during the crisis — and has never recovered. For six consecutive years, P/B has oscillated between 0.3x and 0.6x. The 5-year average is 0.46x. At current levels (0.53x), the stock trades slightly above its post-crisis average, reflecting cautious optimism around the IHC deal. To re-rate to 1.0x book ($2.88), the company needs ROE sustainably above 12% — more than double the current level.

How It Stacks Up — Peer Comparison

Sammaan Capital's P/B discount to peers is not a mispricing — it is a direct reflection of its ROE deficit. LIC Housing earns 16% ROE and trades at 0.77x book; PNB Housing earns 12.7% and gets 1.4x; Aavas earns 13.9% on a smaller, cleaner book and commands 2.96x. At 5.9% normalized ROE, Sammaan's 0.53x is where the math puts it. The re-rating opportunity is real but requires execution, not hope. SAMMAANCAP uses normalized P/E and NI (excluding FY2025 one-time). AAVAS data is FY2024. All figures converted at current INR/USD rate for comparability.

Fair Value & Scenario

Bear ($1.17, -23%): ROE stays under 5% as the diversified lending pivot stalls. P/B compresses to 0.4x on $2.88 book. This matches the lone analyst target and the 52-week low zone.

Base ($1.76, +15%): IHC-backed management drives modest loan book growth (10-12%), pushing ROE toward 8-9% over 18 months. P/B re-rates to 0.6x on a book growing toward $2.99. The IHC open offer provides a near-term floor.

Bull ($2.88, +88%): The diversification strategy works — 15%+ AUM growth, GNPA held under 2%, operating leverage improves. ROE crosses 12%. The stock reprices to 1.0x book value. This is a 2-3 year scenario.

The range is wide because the outcome is binary: either the new owner can grow the book profitably, or the equity base is too large for the earnings power and ROE stays structurally depressed.

What the Numbers Say

The numbers confirm that Sammaan Capital is a stable, deeply deleveraged lender with clean asset quality — not the distressed shell the 0.53x P/B implies. They contradict the narrative of ongoing deterioration: NII is rising, NPAs have been cleaned to their best level in years, and quarterly profits are steady at $35-39M. What they cannot yet confirm is growth. Watch quarterly AUM trajectory after the IHC deal closes: if the diversified lending push delivers 15%+ loan book growth with GNPA held under 2%, ROE will compound back toward double digits and the P/B re-rates. Until then, 0.53x book is the market saying "prove it."